Log in
NASDAQ:IONS

Ionis Pharmaceuticals Competitors

$51.13
+0.89 (+1.77 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$50.01
Now: $51.13
$51.19
50-Day Range
$45.82
MA: $48.35
$52.51
52-Week Range
$39.32
Now: $51.13
$66.22
Volume415,986 shs
Average Volume905,479 shs
Market Capitalization$7.15 billion
P/E Ratio106.52
Dividend YieldN/A
Beta1.44

Competitors

Ionis Pharmaceuticals (NASDAQ:IONS) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying IONS stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Ionis Pharmaceuticals, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares Amgen and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.60$7.84 billion$14.8215.17
Ionis Pharmaceuticals$1.12 billion6.37$303.26 million$2.0824.58

Amgen has higher revenue and earnings than Ionis Pharmaceuticals. Amgen is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Amgen and Ionis Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1121502.50
Ionis Pharmaceuticals16602.38

Amgen presently has a consensus target price of $254.08, suggesting a potential upside of 13.02%. Ionis Pharmaceuticals has a consensus target price of $68.1818, suggesting a potential upside of 33.35%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Amgen.

Institutional and Insider Ownership

71.7% of Amgen shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Amgen has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.

Profitability

This table compares Amgen and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Ionis Pharmaceuticals7.82%6.56%3.38%

Summary

Amgen beats Ionis Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares Gilead Sciences and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.35$5.39 billion$6.149.78
Ionis Pharmaceuticals$1.12 billion6.37$303.26 million$2.0824.58

Gilead Sciences has higher revenue and earnings than Ionis Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Gilead Sciences and Ionis Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences2151002.30
Ionis Pharmaceuticals16602.38

Gilead Sciences presently has a consensus target price of $76.1538, suggesting a potential upside of 26.86%. Ionis Pharmaceuticals has a consensus target price of $68.1818, suggesting a potential upside of 33.35%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Gilead Sciences.

Institutional and Insider Ownership

77.9% of Gilead Sciences shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Gilead Sciences has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Ionis Pharmaceuticals7.82%6.56%3.38%

Summary

Ionis Pharmaceuticals beats Gilead Sciences on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Vertex Pharmaceuticals and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Ionis Pharmaceuticals7.82%6.56%3.38%

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion14.16$1.18 billion$4.2952.85
Ionis Pharmaceuticals$1.12 billion6.37$303.26 million$2.0824.58

Vertex Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vertex Pharmaceuticals and Ionis Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals082212.77
Ionis Pharmaceuticals16602.38

Vertex Pharmaceuticals presently has a consensus target price of $290.5862, suggesting a potential upside of 28.18%. Ionis Pharmaceuticals has a consensus target price of $68.1818, suggesting a potential upside of 33.35%. Given Ionis Pharmaceuticals' higher possible upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Vertex Pharmaceuticals.

Summary

Vertex Pharmaceuticals beats Ionis Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

85.9% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Regeneron Pharmaceuticals and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals37.30%26.71%19.39%
Ionis Pharmaceuticals7.82%6.56%3.38%

Valuation & Earnings

This table compares Regeneron Pharmaceuticals and Ionis Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.98$2.12 billion$21.4723.94
Ionis Pharmaceuticals$1.12 billion6.37$303.26 million$2.0824.58

Regeneron Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Regeneron Pharmaceuticals and Ionis Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals0101312.63
Ionis Pharmaceuticals16602.38

Regeneron Pharmaceuticals currently has a consensus target price of $628.52, indicating a potential upside of 22.27%. Ionis Pharmaceuticals has a consensus target price of $68.1818, indicating a potential upside of 33.35%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Ionis Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

78.9% of Biogen shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 0.5% of Biogen shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Biogen and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Ionis Pharmaceuticals7.82%6.56%3.38%

Valuation & Earnings

This table compares Biogen and Ionis Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.61$5.89 billion$33.577.26
Ionis Pharmaceuticals$1.12 billion6.37$303.26 million$2.0824.58

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Biogen is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Biogen has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Biogen and Ionis Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5151302.24
Ionis Pharmaceuticals16602.38

Biogen currently has a consensus target price of $305.9032, indicating a potential upside of 25.48%. Ionis Pharmaceuticals has a consensus target price of $68.1818, indicating a potential upside of 33.35%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.

Seagen (NASDAQ:SGEN) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

92.0% of Seagen shares are held by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Seagen and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen-25.17%-18.32%-15.49%
Ionis Pharmaceuticals7.82%6.56%3.38%

Valuation & Earnings

This table compares Seagen and Ionis Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million33.26$-158,650,000.00($1.33)-127.16
Ionis Pharmaceuticals$1.12 billion6.37$303.26 million$2.0824.58

Ionis Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Seagen has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Seagen and Ionis Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen161112.63
Ionis Pharmaceuticals16602.38

Seagen currently has a consensus target price of $176.75, indicating a potential upside of 4.51%. Ionis Pharmaceuticals has a consensus target price of $68.1818, indicating a potential upside of 33.35%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Seagen.

Summary

Ionis Pharmaceuticals beats Seagen on 9 of the 15 factors compared between the two stocks.


Ionis Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$224.81+2.0%$130.88 billion$23.36 billion18.13Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.9$60.03+0.9%$75.25 billion$22.45 billion61.89Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$226.71+3.8%$58.95 billion$4.16 billion28.63
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.1$514.05+1.1%$54.85 billion$7.86 billion19.90
Biogen logo
BIIB
Biogen
2.0$243.78+0.8%$37.51 billion$14.38 billion8.07Analyst Revision
Seagen logo
SGEN
Seagen
1.4$169.12+2.2%$30.49 billion$916.71 million-112.00Analyst Downgrade
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.0$123.83+0.7%$27.10 billion$4.99 billion28.93
Incyte logo
INCY
Incyte
1.5$83.25+2.5%$18.23 billion$2.16 billion-53.03
Exact Sciences logo
EXAS
Exact Sciences
1.6$118.19+2.0%$17.78 billion$876.29 million-53.48
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$129.86+3.4%$15.09 billion$219.75 million-16.58Analyst Report
Analyst Revision
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.0$80.40+2.8%$14.60 billion$1.70 billion18.40
Repligen logo
RGEN
Repligen
1.4$186.99+3.0%$9.84 billion$270.24 million322.40
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$95.56+0.5%$8.93 billion$788.10 million45.29Analyst Downgrade
Novavax logo
NVAX
Novavax
1.8$125.69+18.4%$8.00 billion$18.66 million-45.71
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$23.24+2.1%$6.06 billion$182.24 million-20.21
United Therapeutics logo
UTHR
United Therapeutics
1.4$135.54+0.3%$6.02 billion$1.45 billion13.92
Exelixis logo
EXEL
Exelixis
1.9$19.41+3.5%$6.02 billion$967.78 million40.44Insider Selling
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.23+2.3%$5.44 billion$195.99 million251.44Analyst Report
Insider Selling
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$82.83+2.9%$4.39 billion$1.11 billion26.63
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$55.81+3.2%$3.86 billion$36.13 million-83.30
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$65.90+0.6%$3.83 billion$806.43 million-9.33
Alkermes logo
ALKS
Alkermes
1.3$18.50+0.4%$2.94 billion$1.17 billion-40.22
OPKO Health logo
OPK
OPKO Health
1.9$4.13+4.4%$2.77 billion$901.90 million-12.51
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$11.83+1.7%$1.89 billion$428.41 million17.14
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.9$119.11+6.0%$1.84 billionN/A-10.76
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$10.12+3.5%$1.43 billion$102.43 million-12.19
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$85.92+1.7%$1.38 billion$120.28 million-86.79
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$17.78+2.4%$1.34 billion$638.60 million-6.63
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$37.27+0.3%$1.23 billion$252 million-3.60
Innoviva logo
INVA
Innoviva
1.1$10.85+2.7%$1.10 billion$261.02 million5.54
Codexis logo
CDXS
Codexis
1.1$18.01+0.8%$1.07 billion$68.46 million-51.46
ImmunoGen logo
IMGN
ImmunoGen
1.7$5.52+4.0%$1.04 billion$82.27 million-12.84Analyst Upgrade
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.6$5.13+7.2%$905.78 million$48.83 million-6.75
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.4$22.75+4.4%$900.15 million$3.57 million-10.20
MannKind logo
MNKD
MannKind
0.9$3.08+4.2%$716.41 million$63.04 million-14.67
Agenus logo
AGEN
Agenus
1.6$3.71+5.4%$705.45 million$150.05 million-3.40
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$4.73+3.6%$690.21 million$109.33 million-3.88
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.2$12.41+2.4%$678.73 million$227.19 million5.94Analyst Downgrade
Heavy News Reporting
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.50+0.1%$650.03 million$38.19 million37.50
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.91+0.3%$623.59 million$150,000.00-4.16
Geron logo
GERN
Geron
1.4$1.87+3.2%$580.58 million$460,000.00-5.34
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$4.79+11.3%$527.73 million$35.22 million-3.50
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.11+5.8%$525.53 million$59.29 million-22.21
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.8$13.75+0.0%$477.47 million$327.75 million-1.89
Molecular Templates logo
MTEM
Molecular Templates
1.6$9.12+3.1%$455.67 million$22.27 million-4.47
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$4.76+6.7%$420.40 million$143.01 million-0.91
XOMA logo
XOMA
XOMA
1.4$32.05+1.9%$353.26 million$18.37 million-28.87Analyst Report
Insider Selling
Verastem logo
VSTM
Verastem
1.5$1.99+14.6%$337.85 million$17.46 million-1.41High Trading Volume
Unusual Options Activity
Heavy News Reporting
PDL BioPharma logo
PDLI
PDL BioPharma
1.3$2.59+1.2%$295.85 million$54.76 million-1.95
Fortress Biotech logo
FBIO
Fortress Biotech
1.3$2.77+5.8%$259.56 million$36.63 million-3.18
This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.